Daniel W Visscher
Overview
Explore the profile of Daniel W Visscher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
5849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ogony J, Hoskin T, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad M, et al.
Breast Cancer Res Treat
. 2022 Nov;
197(2):277-285.
PMID: 36380012
Purpose: Breast cancer risk is elevated in pathogenic germline BRCA 1/2 mutation carriers due to compromised DNA quality control. We hypothesized that if immunosurveillance promotes tumor suppression, then normal/benign breast...
2.
Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, et al.
Cancer Chemother Pharmacol
. 2022 Apr;
89(5):721-735.
PMID: 35435472
Purpose: BRCA1 or BRCA2 mutated cancers (BRCAmut) have intrinsic sensitivity to PARP inhibitors due to deficiency in homologous recombination-mediated DNA repair. There are similarities between BRCAmut and BRCAwt ovarian and...
3.
de Bel T, Litjens G, Ogony J, Stallings-Mann M, Carter J, Hilton T, et al.
NPJ Breast Cancer
. 2022 Jan;
8(1):13.
PMID: 35046392
Convolutional neural networks (CNNs) offer the potential to generate comprehensive quantitative analysis of histologic features. Diagnostic reporting of benign breast disease (BBD) biopsies is usually limited to subjective assessment of...
4.
Wahner Hendrickson A, Visscher D, Hou X, Goergen K, Atkinson H, Beito T, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885153
The poly(ADP-ribose) binding protein CHFR regulates cellular responses to mitotic stress. The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel-treated ovarian cancer. Despite...
5.
Yu J, Qin B, Moyer A, Sinnwell J, Thompson K, Copland 3rd J, et al.
Breast Cancer Res
. 2021 Mar;
23(1):41.
PMID: 33766079
No abstract available.
6.
Kleinstern G, Scott C, Tamimi R, Jensen M, Pankratz V, Bertrand K, et al.
Breast Cancer Res Treat
. 2021 Jan;
187(1):215-224.
PMID: 33392844
Purpose: We evaluated the association of percent mammographic density (PMD), absolute dense area (DA), and non-dense area (NDA) with risk of "intrinsic" molecular breast cancer (BC) subtypes. Methods: We pooled...
7.
Polley M, Leon-Ferre R, Leung S, Cheng A, Gao D, Sinnwell J, et al.
Breast Cancer Res Treat
. 2021 Jan;
185(3):557-566.
PMID: 33389409
Purpose: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by substantial risks of early disease recurrence and mortality. We constructed and validated clinical calculators for...
8.
Bodelon C, Oh H, Derkach A, Sampson J, Sprague B, Vacek P, et al.
NPJ Breast Cancer
. 2020 Sep;
6:41.
PMID: 32964115
Terminal duct lobular units (TDLUs) are the predominant anatomical structures where breast cancers originate. Having lesser degrees of age-related TDLU involution, measured as higher TDLUs counts or more epithelial TDLU...
9.
Sherman M, Vierkant R, Kaggal S, Hoskin T, Frost M, Denison L, et al.
Cancer Prev Res (Phila)
. 2020 Jul;
13(11):967-976.
PMID: 32718942
Over one million women in the United States receive biopsy diagnoses of benign breast disease (BBD) each year, which confer a 1.5-4.0-fold increase in breast cancer risk. Studies in the...
10.
Chatzopoulos K, Collins A, Sotiriou S, Keeney M, Visscher D, Rivera M, et al.
Head Neck Pathol
. 2020 May;
14(4):951-965.
PMID: 32350809
Salivary duct carcinoma (SDC) commonly expresses androgen receptor (AR) and HER2, giving rise to treatment implications. SDC may also express programmed-death-ligand-1 (PD-L1), a predictive marker of response to checkpoint inhibitors....